Compare Micron Technology, Inc. (MU) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Micron Technology, Inc. trades at $1,055.65 (market cap $1.17T), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Micron Technology, Inc. is far larger — about 15.4× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.51%). Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MU | REGN | |
|---|---|---|
Market Cap | $1.17T | $76.14B |
Volume | 29,425,906 | 500,239 |
Sector | Technology | Health |
52-Week High | $1.21K | $852.03 |
52-Week Low | $181.60 | $557.73 |
Typical Hold Time | 48 Days | 107 Days |
Enterprise Value | $1.13T | $70.85B |
Dividend Yield | 0.06% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,088, up 4.06% today, reflecting strong momentum amid a bullish technical outlook. The stock shows robust fundamentals with a P/E of 14.64, net income margin of 63.8%, and three consecutive quarterly earnings beats. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus favoring Buy ratings (82.85%) and a $1,590 price target. Key risks include cyclical memory pricing and slowing growth projections, but institutional sentiment and cash flow trends support upside potential for investors seeking AI-driven semiconductor exposure.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
